Novacyt SA (OTCPK:NVYTF)

$ 0.95699 0 (0%) Market Cap: 59.05 Mil Enterprise Value: 32.49 Mil PE Ratio: 0 PB Ratio: 0.63 GF Score: 37/100

Half Year 2024 Novacyt SA Earnings Call Transcript

Sep 26, 2024 / 10:00AM GMT

Release Date Price: $0.95699

Transcript

Key Points

Positve

Successful resolution of the DHSC dispute resulted in a net cash inflow of over GBP7 million.
Year-on-year revenue increased by GBP7 million to over GBP10 million, driven by the inclusion of Yourgene sales.
Strong growth in key product areas: cystic fibrosis product growing at 30% and NIPT product at 12%.
Achieved cost savings of GBP5 million, 18 months ahead of schedule.
Cash position strengthened to GBP36.5 million by the end of August 2024.

Negative

Reported a loss after tax of GBP17.7 million in H1 2024.
EBITDA remained flat year-on-year at a loss of GBP5.6 million.
OpEx increased to GBP32 million due to a GBP20 million bad debt provision.
Revenue from the Ranger Technology segment slightly down year-on-year.
Limited material news flow, leading to potential investor concerns.

Operator

Good morning, and welcome to the Novacyt Investor presentation. (Operator Instructions) Before we begin, I'd like to submit the following poll. For the benefit of those joining us from France.

(spoken in foreign language) I'd now like to hand you over to Lyn Rees. Good morning to you sir.

Lyn Rees

Novacyt SA - Chief Executive Officer

Thank you very much, and good morning, everyone. And obviously, thank you for joining us and taking some time out to listen to our interim presentation this morning. Presenting to you today myself, I'm now the CEO of Novacyt in situation since May 1.

Prior to that, I spent six years at Yourgene and prior to that, I was with BBI so in the industry for 20 odd years plus the mode of acquisitions and looking forward to presenting the results today alongside me, we have Steve.

Steve Gibson

Novacyt SA - Chief Financial Officer

Hey, good morning, everyone. Thanks, Lyn, say Steve Gibson on the CFO there with no oversight now around seven and a half years and prior to that,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.